-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 10, Bristol-Myers Squibb (BMS) and Century Therapeutics (“Century”) announced a research collaboration and license agreement to jointly develop and commercialize iPSC-derived allogeneic cell therapies planned for the treatment of Hematological malignancies and solid tumors
Under the terms of the collaboration, Century will be responsible for developing candidate discovery and preclinical development activities
Century mainly focuses on the development of allogeneic T cell therapy or NK cell therapy, its allogeneic T cell therapy by knockout
β2M, CIITA and knock-in HLA-E for allogeneic therapy
Original in English: https://investors.
https://investors.
centurytx.
com/news-releases/news-release-details/century-therapeutics-and-bristol-myers-squibb-enter-strategic